Cargando…

PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms

Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as well as long-term hypertension induced heart failure. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Deres, Laszlo, Bartha, Eva, Palfi, Anita, Eros, Krisztian, Riba, Adam, Lantos, Janos, Kalai, Tamas, Hideg, Kalman, Sumegi, Balazs, Gallyas, Ferenc, Toth, Kalman, Halmosi, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094529/
https://www.ncbi.nlm.nih.gov/pubmed/25014216
http://dx.doi.org/10.1371/journal.pone.0102148
_version_ 1782325846922493952
author Deres, Laszlo
Bartha, Eva
Palfi, Anita
Eros, Krisztian
Riba, Adam
Lantos, Janos
Kalai, Tamas
Hideg, Kalman
Sumegi, Balazs
Gallyas, Ferenc
Toth, Kalman
Halmosi, Robert
author_facet Deres, Laszlo
Bartha, Eva
Palfi, Anita
Eros, Krisztian
Riba, Adam
Lantos, Janos
Kalai, Tamas
Hideg, Kalman
Sumegi, Balazs
Gallyas, Ferenc
Toth, Kalman
Halmosi, Robert
author_sort Deres, Laszlo
collection PubMed
description Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as well as long-term hypertension induced heart failure. In this study, we examined whether PARP-inhibitor (L-2286) treatment could prevent the development of hypertensive cardiopathy in SHRs. 6-week-old SHR animals were treated with L-2286 (SHR-L group) or placebo (SHR-C group) for 24 weeks. Wistar-Kyoto rats were used as aged-matched, normotensive controls (WKY group). Echocardiography was performed, brain-derived natriuretic peptide (BNP) activity and blood pressure were determined at the end of the study. We detected the extent of fibrotic areas. The amount of heat-shock proteins (Hsps) and the phosphorylation state of Akt-1(Ser473), glycogen synthase kinase (GSK)-3β(Ser9), forkhead transcription factor (FKHR)(Ser256), mitogen activated protein kinases (MAPKs), and protein kinase C (PKC) isoenzymes were monitored. The elevated blood pressure in SHRs was not influenced by PARP-inhibitor treatment. Systolic left ventricular function and BNP activity did not differ among the three groups. L-2286 treatment decreased the marked left ventricular (LV) hypertrophy which was developed in SHRs. Interstitial collagen deposition was also decreased by L-2286 treatment. The phosphorylation of extracellular signal-regulated kinase (ERK)1/2(Thr183-Tyr185), Akt-1(Ser473), GSK-3β(Ser9), FKHR(Ser256), and PKC ε(Ser729) and the level of Hsp90 were increased, while the activity of PKC α/βII(Thr638/641), ζ/λ(410/403) were mitigated by L-2286 administration. We could detect signs of LV hypertrophy without congestive heart failure in SHR groups. This alteration was prevented by PARP inhibition. Our results suggest that PARP-inhibitor treatment has protective effect already in the early stage of hypertensive myocardial remodeling.
format Online
Article
Text
id pubmed-4094529
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40945292014-07-15 PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms Deres, Laszlo Bartha, Eva Palfi, Anita Eros, Krisztian Riba, Adam Lantos, Janos Kalai, Tamas Hideg, Kalman Sumegi, Balazs Gallyas, Ferenc Toth, Kalman Halmosi, Robert PLoS One Research Article Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as well as long-term hypertension induced heart failure. In this study, we examined whether PARP-inhibitor (L-2286) treatment could prevent the development of hypertensive cardiopathy in SHRs. 6-week-old SHR animals were treated with L-2286 (SHR-L group) or placebo (SHR-C group) for 24 weeks. Wistar-Kyoto rats were used as aged-matched, normotensive controls (WKY group). Echocardiography was performed, brain-derived natriuretic peptide (BNP) activity and blood pressure were determined at the end of the study. We detected the extent of fibrotic areas. The amount of heat-shock proteins (Hsps) and the phosphorylation state of Akt-1(Ser473), glycogen synthase kinase (GSK)-3β(Ser9), forkhead transcription factor (FKHR)(Ser256), mitogen activated protein kinases (MAPKs), and protein kinase C (PKC) isoenzymes were monitored. The elevated blood pressure in SHRs was not influenced by PARP-inhibitor treatment. Systolic left ventricular function and BNP activity did not differ among the three groups. L-2286 treatment decreased the marked left ventricular (LV) hypertrophy which was developed in SHRs. Interstitial collagen deposition was also decreased by L-2286 treatment. The phosphorylation of extracellular signal-regulated kinase (ERK)1/2(Thr183-Tyr185), Akt-1(Ser473), GSK-3β(Ser9), FKHR(Ser256), and PKC ε(Ser729) and the level of Hsp90 were increased, while the activity of PKC α/βII(Thr638/641), ζ/λ(410/403) were mitigated by L-2286 administration. We could detect signs of LV hypertrophy without congestive heart failure in SHR groups. This alteration was prevented by PARP inhibition. Our results suggest that PARP-inhibitor treatment has protective effect already in the early stage of hypertensive myocardial remodeling. Public Library of Science 2014-07-11 /pmc/articles/PMC4094529/ /pubmed/25014216 http://dx.doi.org/10.1371/journal.pone.0102148 Text en © 2014 Deres et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Deres, Laszlo
Bartha, Eva
Palfi, Anita
Eros, Krisztian
Riba, Adam
Lantos, Janos
Kalai, Tamas
Hideg, Kalman
Sumegi, Balazs
Gallyas, Ferenc
Toth, Kalman
Halmosi, Robert
PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
title PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
title_full PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
title_fullStr PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
title_full_unstemmed PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
title_short PARP-Inhibitor Treatment Prevents Hypertension Induced Cardiac Remodeling by Favorable Modulation of Heat Shock Proteins, Akt-1/GSK-3β and Several PKC Isoforms
title_sort parp-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, akt-1/gsk-3β and several pkc isoforms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094529/
https://www.ncbi.nlm.nih.gov/pubmed/25014216
http://dx.doi.org/10.1371/journal.pone.0102148
work_keys_str_mv AT dereslaszlo parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT barthaeva parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT palfianita parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT eroskrisztian parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT ribaadam parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT lantosjanos parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT kalaitamas parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT hidegkalman parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT sumegibalazs parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT gallyasferenc parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT tothkalman parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms
AT halmosirobert parpinhibitortreatmentpreventshypertensioninducedcardiacremodelingbyfavorablemodulationofheatshockproteinsakt1gsk3bandseveralpkcisoforms